Recombinant human erythropoietin-Fc fusion protein (Longyan)
重组人促红细胞生成素-Fc融合蛋白（隆延生物）
Report date: 2022/01/28 17:29:22
Base Information
Drug NameRecombinant human erythropoietin-Fc fusion protein (Longyan)
Drug Alias NameN/A
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesLongyan Biotechnology (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesLongyan Biotechnology (Shanghai) Co Ltd
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A